<DOC>
	<DOCNO>NCT01269385</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , alemtuzumab rituximab , kill chronic lymphocytic leukemia ( CLL ) cell effective therapy disease . Biological therapy , Imprime PGG ( poly- ( 1-6 ) -beta-glucotriosyl- ( 1-3 ) -beta-glucopyranose ) , may stimulate immune system different way help monoclonal antibody kill CLL cell . Giving PGG beta-glucan together alemtuzumab rituximab could make therapy monoclonal antibody , alemtuzumab rituximab , effective . PURPOSE : This phase I/II trial study side effect best dose PGG beta-glucan give together alemtuzumab rituximab see well work treat patient earlier stage high-risk chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Imprime PGG , Alemtuzumab , Rituximab Treating Patients With High Risk Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose PGG beta glucan combination alemtuzumab rituximab . ( Phase I ) II . Assess rate complete response patient high-risk , early-intermediate stage CLL treat alemtuzumab , rituximab , PGG beta glucan meeting standard National Cancer Institute-International Workshop Chronic Lymphocytic Leukemia ( NCI-IWCLL ) criterion ( Hallek , Cheson et al . 2008 ) treatment . ( Phase II ) SECONDARY OBJECTIVES : I . To monitor assess toxicity regimen . II . Clinical evaluation toxicity . III . Serial monitoring cytomegalovirus ( CMV ) viral load polymerase chain reaction ( PCR ) . IV . To assess rate overall response CLL patient use treatment regimen . V. To determine time progression , time next treatment , duration response CLL patient use treatment regimen . TERTIARY OBJECTIVES : I . To assess correlation individual prognostic marker ( 17p- , 11q- , unmutated VH gene , use VH3-21 , ZAP70+ , CD38+ ) clinical outcome . II . To assess response combination regimen use expanded definition response , include bone marrow study immunohistochemical study residual CLL cell sensitive flow cytometry minimal residual disease patient complete clinical remission . OUTLINE : This phase I , dose-escalation study PGG beta-glucan follow phase II study . Patients receive PGG beta-glucan intravenously ( IV ) 2-4 hour day 1 , 5 , 10 , 17 , 24 , 31 ; alemtuzumab subcutaneously ( SC ) day 3 , 4 , 5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 , 29 , 31 , 33 ; rituximab IV day 10 , 17 , 24 , 31 . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow monthly 3 month , every 3 month 1 year , every 6 month 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis CLL ( Hallek , Cheson et al . 2008 ) manifest : Minimum threshold peripheral lymphocyte count 5 x 10^9/L AND immunophenotypic demonstration population B lymphocytes ( defined CD19+ ) monoclonal ( light chain exclusion ) ; CLL diagnose cell &gt; = 3 follow characteristic : CD5+ , CD23+ , dim surface light chain expression , dim surface CD20 expression AND fluorescence situ hybridization ( FISH ) analysis negative IGH/CCND1 and/or immunostaining negative cyclin D1 expression &gt; = 1 follow poor prognosis factor : unmutated IGHV ( &lt; 2 % ) AND CD38 expression ( &gt; = 30 % cell positive flow cytometry ) ; unmutated IGHV ( &lt; 2 % ) AND ZAP70 expression ( &gt; = 20 % cell positive flow cytometry ) ; use VH321 gene segment irrespective mutation status AND CD38 expression ( &gt; = 30 % cell positive flow cytometry ) ; use VH321 gene segment irrespective mutation status AND ZAP70 expression ( &gt; = 20 % cell positive flow cytometry ) ; 11q22 ; 17p13 Rai classification Stage 0 , I II meet standard NCIIWCLL criterion treatment CLL ( Hallek , Cheson et al . 2008 ) Limited CLL disease burden lymph node &gt; 5 cm diameter splenomegaly &lt; 6 cm leave costal margin midclavicular line rest Creatinine = &lt; 1.5 x upper normal limit ( UNL ) Total bilirubin = &lt; 3.0 x UNL ; total elevate , direct bilirubin perform = &lt; 1.5 x UNL AST = &lt; 3.0 x UNL Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) : 0 , 1 , 2 Negative serum pregnancy test do = &lt; 7 day prior registration , woman childbearing potential Provide inform write consent Willing return Lymphoma Specialized Program Research Excellence ( SPORE ) enrol institution followup Willing provide blood sample correlative research purpose Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception New York Heart Association Class III IV heart disease Recent myocardial infarction ( &lt; 1 month ) Uncontrolled infection Infection human immunodeficiency virus/acquired immune deficiency syndrome ( HIV/AIDS ) , serological evidence active hepatitis B infection ( HBsAg HBeAg positive ) positive hepatitis C serology , severe immunosuppression regimen may occur Evidence active autoimmune hemolytic anemia , immune thrombocytopenia , pure red blood cell aplasia Other active primary malignancy require treatment limit survival = &lt; 2 year Any major surgery = &lt; 4 week prior registration Any previous chemotherapy monoclonal antibody treatment CLL Current use corticosteroid ; NOTE : previous corticosteroid allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Imprime PGG</keyword>
</DOC>